National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov
In English | En español
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

siplizumab
A monoclonal immunoglobulin G1 antibody with potential antineoplastic activity. Siplizumab binds to CD2, a specific receptor found in T cells and NK cells, thereby triggering a host immune response that results in lysis of CD2+ cells, selective suppression of the immune system, and control of activated T cell growth. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonym:anti-CD2 monoclonal antibody
Code name:MEDI-507



Previous:Silybin-Phytosome, silymarin, Simulect, simvastatin, Singulair
Next:sipuleucel-T, siRNA-expressing SV40 vector, sirolimus, sivifene gel, SJG-136

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov